October 28th 2024
Oral function should be measured routinely to determine individual bulbar involvement stages in spinal muscular atrophy (SMA).
October 27th 2024
Bimekizumab Elicits Clinically Meaningful Responses in Moderate to Severe Hidradenitis Suppurativa
May 24th 2024Newly published findings from the pivotal phase 3 BE HEARD I and BE HEARD II trials demonstrated that bimekizumab was well tolerated and produced clinically meaningful responses in patients with moderate to severe hidradenitis suppurativa.
Read More
Glucocorticoids Reduce Comorbidity Frequency in Adults With DMD, Study Finds
May 23rd 2024A retrospective analysis found glucocorticoid treatment to reduce comorbidities in adults with Duchenne muscular dystrophy (DMD) and assessed the relationship between anthropometric measures and respiratory function and functional abilities.
Read More
Study Challenges Rapid-Onset Gender Dysphoria Claims With Longitudinal Data
May 23rd 2024The data refute the rapid-onset gender dysphoria hypothesis by showing that the initially higher depressive symptoms reported by youths transitioning from cisgender to transgender or gender diverse were not significant after accounting for exposure to LGBT violence, the researchers wrote.
Read More
Ryplazim Marks First FDA Approval for Plasminogen Deficiency: Dr Amy Shapiro
May 20th 2024Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, continues her discussion on plasminogen deficiency type 1 by highlighting the recent FDA approval of plasminogen (Ryplazim; Kedrion Biopharma), the first treatment specifically indicated for this disorder.
Watch
As AI Utilization Advances in Health Care, Experts at ATS 2024 Share Insights
May 20th 2024Fatima Rodriguez, MD, MPH, from Stanford University, and Matthew DeCamp, MD, PhD, from the University of Colorado, joined Michael Howell, MD, MPH, of Google, on the stage at ATS 2024 to discuss artificial intelligence (AI) in health care.
Read More
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More